Silencing of SENP1 has also been reported to suppress the expression of several AR target genes and to inhibit androgen-stimulated proliferation of LNCaP cells, thus the SUMOylation pathway is a potential therapeutic target for prostate cancer (Kaikkonen et al. 2009). This evidence concerns the gene AR and prostate carcinoma.